Treatment with aripiprazole solution for injection should be discontinued for all formulations of aripiprazole, excluding Abilify MyCite. (tablet with
aripiprazole), the first injection of aripiprazole ER injectable should be Discontinuation rates due to side effects were low for both Abilify Asimtufii.
Reproductive System and Breast Disorders: infrequent - erectile dysfunction did not lead to discontinuation of any adult patients on ABILIFY Injection.
960 mg in place of the next scheduled injection of the Abilify Maintena. Discontinuation rates due to side effects were low for both Abilify Asimtufii.
Treatment with ABILIFY solution for injection should be discontinued as soon as clinically appropriate and the use of oral aripiprazole should be initiated.
controlled trials, but did not lead to discontinuation of any adult patients on. ABILIFY Injection. infrequent - erectile dysfunction; rare – gynaecomastia
Otsuka has discontinued Abilify Discmelt oral disintegrating tablets. The company has also discontinued the oral solution and injection. Trigen introduced aripiprazole oral disintegrating tablets in 2024. Abilify oral tablets and generic aripiprazole oral tablets are not affected.
Otsuka has discontinued Abilify Discmelt oral disintegrating tablets. The company has also discontinued the oral solution and injection. Trigen introduced
The Abilify injection brand name product (short-acting product) has been discontinued by the manufacturer. Abilify Maintena long-acting
Comments